pasireotide

04/01/2014 - "A 16-week, Phase II trial showed that pasireotide may be an effective treatment for acromegaly. "
06/01/2010 - "Pasireotide is a promising treatment for acromegaly. "
01/01/2013 - ", long-term safety and efficacy of pasireotide in patients with acromegaly and/or Cushing's disease are not fully clear."
11/01/2014 - "This randomized, open-label, Phase I study evaluated the safety, PK, and PD of pasireotide LAR 20, 40, or 60 mg/month in patients with acromegaly. "
11/01/2014 - "Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study."

12/01/2015 - "In 25 % of patients (two patients), a marked tumor shrinkage was recorded, with tumor mass disappearance in one case; this tumor shrinkage was associated to rapid and sustained biochemical remission up to 24 months of continuous pasireotide treatment. "
05/01/2015 - "Further studies are needed to evaluate the efficacy of novel SSAs such as pasireotide in the refractory setting, and the role of high-dose SSAs for symptom and tumor control."
07/01/2013 - "In this case study, long-term pasireotide treatment as first-line therapy led to normalization of UFC, reduction of tumor volume and significant improvement in the clinical signs and symptoms of Cushing's disease."
08/01/2014 - "Pasireotide offers a tumor-directed medical therapy that may be effective for the extended treatment of some patients with Cushing's disease."
12/01/2015 - "The current study aimed at investigating the effects of long-term treatment with pasireotide (up to 24 months) on tumor mass in a group of patients with CD, participating to a phase III study. "

07/01/2010 - "If the efficacy of pasireotide is confirmed by larger studies, this compound may be a useful treatment option not only in patients with severe Cushing's disease, but also in patients with mild hypercortisolism where its efficacy might be more evident."
03/01/2015 - "Pasireotide was effective in reducing hypercortisolism and mass volume, combined with TMZ in one case. "
01/01/2015 - "Pasireotide has been recently approved by the European Medical Agency and the US Food and Drug Administration for treating adults with CD with recurrent hypercortisolism after surgery, or for whom surgery is not an option. "
09/01/2012 - "Drugs in the medical treatment of Cushing's syndrome--an update on mifepristone and pasireotide."
03/01/2014 - "Occurrence of De Quervain's Thyroiditis after Resolution of Hypercortisolism following Pasireotide Treatment for Cushing's Disease and Surgery for an Adrenocortical Adenoma: Report of Two Cases."

06/01/2010 - "bid, 19% of patients achieved a biochemical response, which increased to 27% after 3 months of pasireotide; 39% of patients had a more than 20% reduction in pituitary tumor volume. "
06/01/2007 - "Some studies have shown that SSTR5 is predominantly expressed in corticotroph pituitary adenomas and that SOM230 has more efficacy than octreotid in the treatment of Cushing disease. "
06/01/2004 - "SOM230 inhibited GH release from GH-secreting adenoma cultures by 34 +/- 8% (P = 0.002), PRL by 35 +/- 4% from PRL-secreting adenomas (P = 0.01), and alpha-subunit secretion from nonfunctioning pituitary adenomas by 46 +/- 18% (P = 0.34). "
01/01/2010 - "Adrenocorticotropic hormone-secreting pituitary adenomas predominantly express sst(5), followed by sst(2) and sst(1), suggesting that pasireotide may be effective in the treatment of Cushing's disease. "
09/01/2012 - "This argues against a direct adrenal involvement in the clinical efficacy of SOM230 in patients with ACTH-secreting pituitary tumors and widens the known range of action of SOM230."

08/01/2013 - "This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics profiles of pasireotide long-acting release (LAR) formulation in patients with advanced gastroenteropancreatic neuroendocrine tumor (GEP NET) refractory to other SSAs. "
02/01/2015 - "Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors."
10/01/2012 - "Cohorts of patients with advanced neuroendocrine tumors were treated with escalating doses of pasireotide (600-1200  μg s.c. "
02/01/2013 - "Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors."
02/01/2015 - "Results from preclinical studies indicate that pasireotide can inhibit neuroendocrine tumor (NET) growth more robustly than octreotide in vitro. "